Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Volumn 18, Issue 5, 2004, Pages 343-347

  McCormack, Paul L ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE; INTERFERON BETA-1B;

CHEMISTRY; DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MULTICENTER STUDIES; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 28744441041     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418050-00006     Document Type: Review

References (49)